Atlas Trials

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Clinical trial NCT02590432 · COMPLETED

Trial details

NCT number
NCT02590432
Sponsor
Forest Laboratories
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Irritable Bowel Syndrome With ConstipationChronic Idiopathic Constipation
Start date
2015-11-01
Primary completion
2018-02-05
Enrollment
828

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.